+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antipsychotic Drugs Market by Drug Type, Disease Indication, Therapeutic Class, Route of Administration, Distribution Channel - Global Forecast 2026-2032- Product Image
Antipsychotic Drugs Market by Drug Type, Disease Indication, Therapeutic Class, Route of Administration, Distribution Channel - Global Forecast 2026-2032- Product Image
Sale

Antipsychotic Drugs Market by Drug Type, Disease Indication, Therapeutic Class, Route of Administration, Distribution Channel - Global Forecast 2026-2032

  • Report

  • 186 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 5305498
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Antipsychotic Drugs Market is projected to reach USD 16.81 Billion in 2026. It is expected to continue growing at a CAGR of 8.29%, reaching USD 27.16 Billion by 2032.

The antipsychotic drugs market is anchored by the persistent clinical burden of schizophrenia, bipolar disorder, acute psychosis, and adjunctive treatment needs in major depressive disorder. The World Health Organization estimates that schizophrenia affects about 24 million people globally, while bipolar disorder affects around 40 million people, creating sustained demand for effective, tolerable, and accessible psychosis therapeutics.

Market momentum is being shaped by continued use of second-generation antipsychotics, broad generic availability, and rising adoption of long-acting injectable antipsychotics designed to address relapse linked to poor adherence. At the same time, the 2024 U.S. FDA approval of xanomeline and trospium chloride for schizophrenia signaled renewed interest in non-dopamine mechanisms, expanding the competitive landscape beyond traditional dopamine D2 receptor modulation.

Transformative Shifts in the Antipsychotic Treatment Landscape

The landscape is shifting from symptom suppression alone toward relapse prevention, functional recovery, and personalized safety management. Long-acting injectables are gaining clinical relevance because relapse, hospitalization, and treatment discontinuation remain major cost drivers in schizophrenia care. Health systems are increasingly evaluating antipsychotic therapies through total cost of care, not only unit price.

Scientific innovation is also changing competitive positioning. Established atypical antipsychotics continue to dominate prescribing due to familiarity and generic access, but new mechanisms involving muscarinic receptors, TAAR1 pathways, glutamatergic modulation, and adjunctive digital adherence tools are reshaping research priorities. Regulatory expectations around metabolic risk, extrapyramidal symptoms, sedation, cardiovascular safety, and real-world evidence are becoming central to product differentiation.

Cumulative Impact of Artificial Intelligence on Antipsychotic Drugs

Artificial intelligence is having a cumulative impact across antipsychotic drug discovery, clinical development, pharmacovigilance, and commercial strategy. In discovery, AI-enabled modeling is being used to screen compounds, predict receptor-binding profiles, and identify safety liabilities earlier. In clinical development, machine learning can support site selection, patient stratification, relapse-risk prediction, and analysis of complex endpoints in schizophrenia and bipolar disorder trials.

The strongest near-term value is likely to come from practical applications such as adverse-event signal detection, medication adherence analytics, and precision prescribing support. However, AI tools must be validated against diverse patient populations because psychosis care is highly sensitive to bias, privacy risk, and social determinants of health. Organizations that combine AI with regulated evidence standards will be better positioned to improve antipsychotic therapy outcomes.

Key Regional Insights Across Global Antipsychotic Demand

North America remains a leading region for antipsychotic drugs due to high diagnosis rates, advanced psychiatric care infrastructure, payer coverage, and rapid uptake of innovative therapies. The United States is especially influential because FDA approvals, mental health parity initiatives, and specialist prescribing patterns often shape global launch sequencing. Canada supports demand through public drug plans and structured mental health services, although reimbursement assessments can influence speed of access.

Europe is characterized by mature prescribing, strong pharmacovigilance, and cost-containment policies across national health systems. The European Union emphasizes health technology assessment, real-world evidence, and equitable access, while the United Kingdom, Germany, France, Italy, and Spain each balance innovation with generic substitution and budget control. Asia-Pacific is expanding through rising mental health awareness, increasing psychiatric service capacity, and large patient pools in China, India, Japan, South Korea, and Australia.

Latin America shows growing demand led by Brazil and Mexico, but access variability, public-sector procurement cycles, and affordability barriers remain important. The Middle East, particularly GCC markets, is investing in specialty care and hospital infrastructure, while Africa continues to face a large treatment gap due to limited psychiatric workforce, medicine availability, and financing constraints, consistent with WHO findings that many low- and middle-income settings have limited access to mental health services and essential psychotropic medicines.

Key Group Insights for Antipsychotic Drug Commercial Strategy

Within ASEAN, antipsychotic demand is supported by expanding universal health coverage programs, urban hospital networks, and increasing recognition of severe mental illness, although access differs sharply between higher-income and lower-income member states. GCC countries are prioritizing mental health under national healthcare transformation agendas, with strong potential for branded therapies and hospital-based specialty care where reimbursement pathways are established.

The European Union represents a highly regulated and value-focused market where pharmacovigilance, health technology assessment, and generic competition shape pricing and uptake. BRICS economies contribute scale, especially through China, India, and Brazil, where large patient populations, local manufacturing, and government procurement strongly influence market structure. G7 countries remain central to innovation, reimbursement policy, and clinical guideline development, while NATO members collectively represent many advanced psychiatric care systems and defense-linked mental health priorities, including growing attention to trauma, depression, substance use, and severe mental illness among service members and veterans.

Key Country Insights in the Antipsychotic Drugs Market

The United States is the most commercially influential country due to high pharmaceutical spending, strong specialty care access, and a clear FDA pathway for novel schizophrenia treatments. Canada offers stable demand through public reimbursement systems, while Mexico and Brazil are important Latin American markets where public procurement, private insurance, and generic affordability define access. In the United Kingdom, National Health Service prescribing and cost-effectiveness reviews influence uptake, while Germany and France remain critical European markets because of structured reimbursement and large treated populations.

Italy and Spain are mature antipsychotic markets with strong generic penetration and regional budget management. Russia maintains demand through public and private channels but faces access and supply-chain complexity. China and India represent major long-term opportunities because of large populations, expanding psychiatric diagnosis, domestic manufacturing capacity, and government-led healthcare access initiatives. Japan has high standards for safety, post-marketing surveillance, and elderly care, Australia supports evidence-based access through national reimbursement, and South Korea combines advanced healthcare infrastructure with growing mental health investment.

Actionable Recommendations for Antipsychotic Industry Leaders

Industry leaders should prioritize differentiated clinical value in relapse prevention, adherence, safety, and quality-of-life outcomes. Long-acting injectables, therapies with improved metabolic profiles, and mechanisms that reduce dopamine-related adverse effects should remain high-priority development and lifecycle-management opportunities. Organizations should also invest in evidence packages that demonstrate reductions in hospitalization, emergency care utilization, and treatment discontinuation.

Commercial teams should localize access strategies by payer type, procurement model, and psychiatric infrastructure. Partnerships with community mental health providers, digital adherence platforms, and pharmacovigilance networks can strengthen real-world performance. Leaders should also build AI governance frameworks to ensure that predictive tools used in trial design, safety monitoring, or patient support meet clinical, ethical, and regulatory expectations.

Research Methodology for Antipsychotic Market Intelligence

This executive summary is built on a structured research approach combining verified secondary research, regulatory intelligence, clinical evidence review, and market triangulation. Core inputs include public information from the World Health Organization, national regulators such as the U.S. FDA and European Medicines Agency, clinical trial registries, peer-reviewed psychiatric literature, drug labels, reimbursement information, treatment guidelines, and public health datasets.

Market interpretation is developed by comparing epidemiology, treatment pathways, product approvals, patent and pipeline activity, payer behavior, pharmacovigilance requirements, and regional access conditions. Insights are validated through cross-source consistency checks and are framed to support strategic decision-making in the antipsychotic drugs market without relying on unsupported claims, market sizing, or speculative forecasts.

Conclusion: Outlook for the Antipsychotic Drugs Market

The antipsychotic drugs market is entering a new phase defined by established atypical therapies, growing use of long-acting injectables, and the emergence of novel mechanisms for schizophrenia treatment. Demand remains structurally supported by the global burden of severe mental illness, while payer scrutiny requires stronger evidence of safety, adherence, relapse prevention, and total cost-of-care benefits.

Organizations that align scientific innovation with real-world access needs will be best positioned for sustainable growth. The strongest competitive advantage will come from therapies and services that improve clinical outcomes, reduce hospitalization, support patient adherence, and address the long-standing treatment gap across both mature and emerging healthcare systems.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Antipsychotic Drugs Market, by Drug Type
7.1. Risperidone
7.2. Quetiapine
7.3. Olanzapine
7.4. Aripiprazole
7.5. Brexpiprazole
7.6. Paliperidone Palmitate
7.7. Haloperidol
7.8. Clozapine
7.9. Ziprasidone
7.10. Lurasidone
8. Antipsychotic Drugs Market, by Disease Indication
8.1. Schizophrenia
8.2. Bipolar Disorder
8.3. Unipolar Depression
8.4. Dementia-related Psychosis
9. Antipsychotic Drugs Market, by Therapeutic Class
9.1. First-Generation Antipsychotics
9.2. Second-Generation Antipsychotics
9.3. Third-Generation
10. Antipsychotic Drugs Market, by Route of Administration
10.1. Oral
10.2. Parenteral
10.3. Transdermal
11. Antipsychotic Drugs Market, by Distribution Channel
11.1. Online
11.2. Offline
12. Asia-Pacific Antipsychotic Drugs Market
13. Europe Antipsychotic Drugs Market
14. North America Antipsychotic Drugs Market
15. Latin America Antipsychotic Drugs Market
16. Africa Antipsychotic Drugs Market
17. Middle East Antipsychotic Drugs Market
18. NATO Antipsychotic Drugs Market
19. G7 Antipsychotic Drugs Market
20. BRICS Antipsychotic Drugs Market
21. European Union Antipsychotic Drugs Market
22. ASEAN Antipsychotic Drugs Market
23. GCC Antipsychotic Drugs Market
24. China Antipsychotic Drugs Market
25. United States Antipsychotic Drugs Market
26. Japan Antipsychotic Drugs Market
27. India Antipsychotic Drugs Market
28. Germany Antipsychotic Drugs Market
29. United Kingdom Antipsychotic Drugs Market
30. Australia Antipsychotic Drugs Market
31. France Antipsychotic Drugs Market
32. South Korea Antipsychotic Drugs Market
33. Italy Antipsychotic Drugs Market
34. Canada Antipsychotic Drugs Market
35. Russia Antipsychotic Drugs Market
36. Brazil Antipsychotic Drugs Market
37. Mexico Antipsychotic Drugs Market
38. Spain Antipsychotic Drugs Market
39. Competitive Landscape
39.1. Market Concentration Analysis, 2025
39.1.1. Concentration Ratio (CR)
39.1.2. Herfindahl Hirschman Index (HHI)
39.2. Recent Developments & Impact Analysis, 2025
39.3. Product Portfolio Analysis, 2025
39.4. Benchmarking Analysis, 2025
40. Company Profiles
40.1. AbbVie Inc.
40.2. Alkermes, Inc.
40.3. AstraZeneca plc
40.4. Dr. Reddy’s Laboratories Ltd.
40.5. Eli Lilly and Company
40.6. Gedeon Richter Plc
40.7. H. Lundbeck A/S
40.8. Intra-Cellular Therapies, Inc.
40.9. Johnson & Johnson
40.10. Karuna Therapeutics, Inc.
40.11. Merck & Co., Inc.
40.12. Novartis AG
40.13. Novartis International AG
40.14. Otsuka Holdings Co., Ltd.
40.15. Pfizer Inc.
40.16. Roche Holding AG
40.17. Sanofi S.A.
40.18. Sumitomo Pharma Co., Ltd.
40.19. Sun Pharmaceutical Industries Ltd.
40.20. Teva Pharmaceutical Industries Ltd.
40.21. Viatris Inc.
40.22. Zydus Lifesciences Ltd.
List of Figures
FIGURE 1. GLOBAL ANTIPSYCHOTIC DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ANTIPSYCHOTIC DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ANTIPSYCHOTIC DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ANTIPSYCHOTIC DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL ANTIPSYCHOTIC DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 23. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 25. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. NATO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 37. NATO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. G7 ANTIPSYCHOTIC DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. G7 ANTIPSYCHOTIC DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. BRICS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. BRICS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. EUROPEAN UNION ANTIPSYCHOTIC DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. EUROPEAN UNION ANTIPSYCHOTIC DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. GCC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. GCC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 49. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 50. JAPAN ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. INDIA ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. GERMANY ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. UNITED KINGDOM ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. FRANCE ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. ITALY ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. CANADA ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. RUSSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. BRAZIL ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. MEXICO ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. SPAIN ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL ANTIPSYCHOTIC DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL RISPERIDONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL RISPERIDONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL RISPERIDONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL QUETIAPINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL QUETIAPINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL QUETIAPINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL OLANZAPINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL OLANZAPINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL OLANZAPINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ARIPIPRAZOLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ARIPIPRAZOLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ARIPIPRAZOLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL BREXPIPRAZOLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL BREXPIPRAZOLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL BREXPIPRAZOLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL PALIPERIDONE PALMITATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL PALIPERIDONE PALMITATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL PALIPERIDONE PALMITATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL HALOPERIDOL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL HALOPERIDOL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL HALOPERIDOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL CLOZAPINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL CLOZAPINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL CLOZAPINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ZIPRASIDONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ZIPRASIDONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ZIPRASIDONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL LURASIDONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL LURASIDONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL LURASIDONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL SCHIZOPHRENIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL SCHIZOPHRENIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL SCHIZOPHRENIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL BIPOLAR DISORDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL BIPOLAR DISORDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL BIPOLAR DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL UNIPOLAR DEPRESSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL UNIPOLAR DEPRESSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL UNIPOLAR DEPRESSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL DEMENTIA-RELATED PSYCHOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL DEMENTIA-RELATED PSYCHOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL DEMENTIA-RELATED PSYCHOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL FIRST-GENERATION ANTIPSYCHOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL FIRST-GENERATION ANTIPSYCHOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL FIRST-GENERATION ANTIPSYCHOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL SECOND-GENERATION ANTIPSYCHOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL SECOND-GENERATION ANTIPSYCHOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL SECOND-GENERATION ANTIPSYCHOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL THIRD-GENERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL THIRD-GENERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL THIRD-GENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL TRANSDERMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL TRANSDERMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL TRANSDERMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 81. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 82. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 83. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 84. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 85. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 87. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 88. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 89. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 90. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 91. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 93. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 94. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 95. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 96. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 97. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 99. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 100. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 101. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 102. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 103. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 104. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 105. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 106. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 107. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 108. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 109. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 110. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 111. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 112. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 113. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 114. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 115. NATO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 116. NATO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 117. NATO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 118. NATO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 119. NATO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 120. NATO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 121. G7 ANTIPSYCHOTIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 122. G7 ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 123. G7 ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 124. G7 ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 125. G7 ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 126. G7 ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 127. BRICS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 128. BRICS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 129. BRICS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 130. BRICS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 131. BRICS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 132. BRICS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 133. EUROPEAN UNION ANTIPSYCHOTIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 134. EUROPEAN UNION ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 135. EUROPEAN UNION ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 136. EUROPEAN UNION ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 137. EUROPEAN UNION ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 138. EUROPEAN UNION ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 139. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 140. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 141. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 142. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 143. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 144. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 145. GCC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 146. GCC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 147. GCC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 148. GCC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 149. GCC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 150. GCC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 151. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 152. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 153. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 154. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 155. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 156. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 157. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 158. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 159. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 160. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 161. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 162. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 163. JAPAN ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 164. JAPAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 165. JAPAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 166. JAPAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 167. JAPAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 168. JAPAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 169. INDIA ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 170. INDIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 171. INDIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 172. INDIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 173. INDIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 174. INDIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 175. GERMANY ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 176. GERMANY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 177. GERMANY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 178. GERMANY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 179. GERMANY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 180. GERMANY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 181. UNITED KINGDOM ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 182. UNITED KINGDOM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 183. UNITED KINGDOM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 184. UNITED KINGDOM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 185. UNITED KINGDOM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 186. UNITED KINGDOM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 187. AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 188. AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 189. AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 190. AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 191. AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 192. AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 193. FRANCE ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 194. FRANCE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 195. FRANCE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 196. FRANCE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 197. FRANCE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 198. FRANCE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 199. SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 200. SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 201. SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 202. SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 203. SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 204. SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 205. ITALY ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 206. ITALY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 207. ITALY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 208. ITALY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 209. ITALY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 210. ITALY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 211. CANADA ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 212. CANADA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 213. CANADA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 214. CANADA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 215. CANADA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 216. CANADA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 217. RUSSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 218. RUSSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 219. RUSSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 220. RUSSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 221. RUSSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 222. RUSSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 223. BRAZIL ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 224. BRAZIL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 225. BRAZIL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 226. BRAZIL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 227. BRAZIL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 228. BRAZIL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 229. MEXICO ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 230. MEXICO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 231. MEXICO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 232. MEXICO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 233. MEXICO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 234. MEXICO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 235. SPAIN ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 236. SPAIN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 237. SPAIN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 238. SPAIN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 239. SPAIN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 240. SPAIN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The companies featured in this Antipsychotic Drugs market report include:
  • AbbVie Inc.
  • Alkermes, Inc.
  • AstraZeneca plc
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • Gedeon Richter Plc
  • H. Lundbeck A/S
  • Intra‑Cellular Therapies, Inc.
  • Johnson & Johnson
  • Karuna Therapeutics, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Novartis International AG
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Sumitomo Pharma Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Ltd.

Table Information

Report AttributeDetails
No. of Pages186
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 16.81 Billion
Forecasted Market Value ( USD ) by 2032 $ 27.16 Billion
Compound Annual Growth Rate8.2%
Regions CoveredGlobal
No. of Companies Mentioned23

Related Topics

Related Reports

Schizophrenia Therapeutics Market - Global Forecast 2026-2032 - Product Image

Schizophrenia Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 191 Pages
  • Global
From
Antipsychotic Drugs Market Forecast to 2033 - Product Image

Antipsychotic Drugs Market Forecast to 2033

  • Report
  • 110 Pages
  • Global
From
Schizophrenia Therapeutics - Global Strategic Business Report - Product Image

Schizophrenia Therapeutics - Global Strategic Business Report

  • Report
  • 236 Pages
  • Global
From
Antipsychotic Drugs - Global Strategic Business Report - Product Image

Antipsychotic Drugs - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Antipsychotic Drugs Market Report 2026 - Product Image

Antipsychotic Drugs Market Report 2026

  • Report
  • 250 Pages
  • Global
From

About the Antipsychotic Drug Market

The Antipsychotic Drug market is a segment of the Central Nervous System Drugs market. Antipsychotic drugs are used to treat mental disorders such as schizophrenia, bipolar disorder, and major depressive disorder. These drugs work by blocking dopamine receptors in the brain, which helps to reduce the symptoms of psychosis. Common side effects of antipsychotic drugs include drowsiness, weight gain, and dry mouth. The Antipsychotic Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Eli Lilly, Pfizer, Johnson & Johnson, Novartis, and AstraZeneca. These companies have a wide range of products, including both branded and generic drugs. Additionally, many of these companies have developed new formulations of existing drugs, such as long-acting injectables, to improve patient compliance. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.